The global multi-center phase-II clinical trial will be a 36-week, multi-center, randomized, double-blind, placebo-controlled trial, followed by a 36-week open-label extension period
Narayanan to lead SeQuent through next phase of consolidation and growth
Their strong recommendation is based on moderate certainty evidence that it improves survival and reduces the need for ventilation
It is the first monoclonal antibody drug for use in any animal species
The new plant at Slovenská ?up?a site in Slovakia is scheduled to come on stream in two years
In-house wet testing with live Omicron virus demonstrated that the Antigen test detects the Omicron variant with comparable sensitivity to other variants
Three Indian firms namely Curisin, Immunidex and Telemedicine Indian company are part of the first phase
New data from ongoing trial showed increased antibody response against Beta, Delta, Alpha, Gamma and Omicron variants following third dose booster with Vaxzevria
Nuvaxovid is the first protein-based Covid-19 vaccine granted approval in South Korea
ICICI Direct gives a preview on the earnings narrative for Q3FY22
Subscribe To Our Newsletter & Stay Updated
